Nikunj Jain - 01 Oct 2025 Form 3 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role: Principal Accounting Officer
Signature: /s/ Scott B. Willoughby, Attorney-in-Fact
Issuer symbol: SGMO
Transactions as of: 01 Oct 2025
Net transactions value: $0
Form type: 3
Filing time: 09 Oct 2025, 18:49:05 UTC
Next filing: 24 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Jain Nikunj	Principal Accounting Officer	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BOULEVARD, RICHMOND	/s/ Scott B. Willoughby, Attorney-in-Fact	09 Oct 2025	0002089213

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SGMO	Common Stock						253,003	01 Oct 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SGMO	Stock Option (Right to Buy)							01 Oct 2025	Common Stock	45,608	$8.77	Direct	F2
holding	SGMO	Stock Option (Right to Buy)							01 Oct 2025	Common Stock	11,892	$8.77	Direct	F2
holding	SGMO	Stock Option (Right to Buy)							01 Oct 2025	Common Stock	24,750	$5.90	Direct	F3
holding	SGMO	Stock Option (Right to Buy)							01 Oct 2025	Common Stock	3,237	$2.66	Direct	F4
holding	SGMO	Stock Option (Right to Buy)							01 Oct 2025	Common Stock	48,513	$2.66	Direct	F4
holding	SGMO	Stock Option (Right to Buy)							01 Oct 2025	Common Stock	99,454	$0.9561	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes (a) 3,235 shares subject to the Reporting Person's February 24, 2023 restricted stock unit ("RSU") grant that will vest in successive equal quarterly installments through February 24, 2026; (b) 37,500 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest in successive equal quarterly installments through January 22, 2026; and (c) 49,726 shares subject to the Reporting Person's February 25, 2025 RSU grant will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
F2	One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F3	Fully vested
F4	One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.